DURECT began life in 1998 dedicated to exploiting the benefits of enhanced drug delivery. Our goal was to optimize the physical, pharmacokinetic, and pharmacodynamic properties of approved active agents in ways that would solve significant clinical problems. In recent years, we have built upon this significant legacy, expanding our reach to encompass the development of a family of endogenous molecules that are entirely new to pharmaceutical research and that show remarkable promise in a number of important therapeutic areas.

Whether taking aim at improved drug formulations or bringing to market therapies based on completely novel molecules and avenues of research, the men and women of DURECT strive to fulfill a fundamental promise to patients, physicians, corporate partners, and investors: create best-in-class pharmaceutical products with enduring value—measured most directly by their potential to make real, palpable differences in the lives of those who need them.

Type
Public
HQ
Cupertino, US
Size (employees)
106 (est)+9%
Website
durect.com
Durect is headquartered in Cupertino, US

Key People at Durect

James E. Brown

James E. Brown

President and Chief Executive Officer
Matthew J. Hogan

Matthew J. Hogan

CFO
Felix Theeuwes

Felix Theeuwes

CSO

Durect Office Locations

Durect has an office in Cupertino
Cupertino, US (HQ)
Durect 10260 Bubb Rd

Durect Data and Metrics

Durect Financial Metrics

Durect's revenue was reported to be $14 m in FY, 2016 which is a 27% decrease from the previous period.
USD

Revenue (FY, 2016)

14 m

Revenue growth (FY, 2015 - FY, 2016), %

(27%)

Gross profit (FY, 2016)

8.7 m

Gross profit margin (FY, 2016), %

62%

Net income (FY, 2016)

(34.5 m)

EBIT (FY, 2016)

(32.4 m)

Market capitalization (26-Jun-2017)

213 m

Closing share price (26-Jun-2017)

1.5

Cash (31-Dec-2016)

5.4 m
Durect's current market capitalization is $213 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

15.3 m19.4 m19.1 m14 m

Revenue growth, %

27%(1%)(27%)

Cost of goods sold

4.8 m5.7 m3.9 m5.3 m

Gross profit

10.5 m13.7 m15.2 m8.7 m

Gross profit Margin, %

68%71%80%62%

R&D expense

18.9 m22.4 m24.3 m29.3 m

General and administrative expense

12.7 m12.3 m11.6 m11.8 m

Operating expense total

36.5 m40.4 m39.8 m46.4 m

EBIT

(21.2 m)(21 m)(20.7 m)(32.4 m)

EBIT margin, %

(138%)(108%)(108%)(231%)

Interest expense

284 k1.2 m2.2 m2.3 m

Interest income

39 k237 k143 k

Net Income

(21.5 m)(22.1 m)(22.7 m)(34.5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

7.8 m2.7 m3.6 m5.4 m

Accounts Receivable

2.3 m2.1 m2.2 m1.2 m

Inventories

3.5 m3.6 m3.9 m3.8 m

Current Assets

28.3 m39.5 m38.3 m32.4 m

PP&E

2 m1.7 m1.6 m1.3 m

Goodwill

6.4 m6.4 m6.4 m6.4 m

Total Assets

40.8 m50.1 m46.8 m40.5 m

Accounts Payable

736 k1 m1.3 m2.1 m

Current Liabilities

7.2 m7 m7.4 m28.8 m

Additional Paid-in Capital

391.5 m401.3 m420.5 m448.4 m

Retained Earnings

(360.8 m)(382.9 m)(405.6 m)(440.1 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(21.5 m)(22.1 m)(22.7 m)(34.5 m)

Depreciation and Amortization

558 k601 k425 k416 k

Accounts Receivable

(183 k)227 k(100 k)1.1 m

Inventories

(681 k)(1.4 m)(579 k)(552 k)

Accounts Payable

(1 m)285 k265 k800 k

Cash From Operating Activities

(15.4 m)(14.2 m)(20.6 m)(27.3 m)

Purchases of PP&E

(69 k)(204 k)(225 k)(147 k)

Cash From Investing Activities

1.1 m(15.7 m)6.3 m6 m

Cash From Financing Activities

11 m24.8 m15.2 m23.1 m

Interest Paid

6 k691 k1.6 m1.6 m
USDY, 2016

Revenue/Employee

143.1 k

Durect Market Value History

Durect Company Life and Culture

You may also be interested in